The story of TLR research begins with the identification of the Toll gene in Drosophila embryogenesis during the 1980s, originally investigated for its role in developmental patterning. This early insight radically shifted in 1996 when Toll was repurposed as a critical regulator of antifungal immunity, validating the concept of pattern recognition receptors (PRRs). This revelation ignited a wave of exploration culminating in the discovery of human TLR4 in 1997 and the genetic confirmation of its role as the endotoxin receptor in 1998. Subsequent research throughout the late 1990s systematically elucidated ligand specificities across TLR family members, alongside the identification of MyD88, a central adaptor molecule indispensable for signal transduction in most TLR pathways.

Since these foundational discoveries, the research landscape has dramatically expanded, as evidenced by an exponential rise in scientific publications dedicated to TLRs and inflammation. The first decade of the 21st century was a particularly productive era marked by the complete mapping of the TLR family, their ligand repertoires, and downstream signaling networks. Groundbreaking studies identified endogenous damage-associated molecular patterns (DAMPs), thereby integrating TLRs into the broader framework of sterile inflammation and the “danger theory.” This period culminated in the 2011 Nobel Prize awarded to Hoffmann and Beutler, celebrating their pioneering insights into innate immunity.

The decade following the Nobel milestone shifted focus toward elucidating the intricate regulatory circuits that modulate TLR activation. It became clear that TLR signaling is not a binary on/off switch but a highly nuanced system modulated at multiple levels. Post-translational modifications—phosphorylation, ubiquitination, methylation, acetylation, SUMOylation, succinylation, and nitrosylation—were discovered to fine-tune the intensity and duration of TLR-induced responses. Concurrently, epigenetic regulation came into view, where DNA methylation, histone modifications, chromatin remodeling, and RNA editing orchestrated the chromatin landscape governing TLR-responsive gene expression patterns over extended periods.

Emerging as an exciting frontier, metabolic reprogramming unveiled bidirectional crosstalk linking cellular energy metabolism and TLR signaling. Fatty acid oxidation, lipid metabolism, and amino acid pathways dynamically interact with innate immune signaling, establishing feedback loops that choreograph immune cell function. Even more revolutionary is the identification of biomolecular condensates driven by phase separation, representing an entirely novel layer of spatial and temporal regulation underlying the assembly and coordination of TLR signaling complexes. This discovery opens new vistas in understanding how cells coordinate innate immune signaling with subcellular architecture.

The review highlights five fundamental modes of cross-regulation that confer remarkable plasticity on TLR pathways. These include the interplay between various post-translational modifications responsive to a single pathogen stimulus, synergistic convergence of metabolic and epigenetic mechanisms forming a stable yet adaptive response framework, the cooperative amplification arising from simultaneous activation of multiple distinct TLRs, mutual regulation among downstream effector pathways, and extensive crosstalk with other pattern recognition receptor systems. Collectively, these layers of regulation ensure that TLR-driven inflammation is both potent against infection and tightly controlled to avoid collateral tissue damage.

Beyond cell-intrinsic events, TLR signaling is deeply embedded within the tissue microenvironment, integrating diverse extrinsic cues. Cytokine milieus, oxygen gradients, nutrient availability, neuroimmune signals, mechanical forces, cell death modalities, and pH fluctuations all converge on TLR networks to tailor context-appropriate immune outcomes. This ecological perspective is crucial for understanding how TLRs govern host responses under varying pathophysiological conditions including infectious diseases, autoimmune disorders, cancer progression, and the chronic low-grade inflammation associated with aging (inflammaging).

The evolutionary arms race between hosts and pathogens adds another layer of complexity. Many microbes have evolved sophisticated strategies to evade TLR surveillance, including masking pathogen-associated molecular patterns (PAMPs), degrading or hijacking key TLR signaling components, exploiting immune dysfunction, and even manipulating phase separation processes. These microbial evasion strategies paradoxically illuminate critical regulatory nodes within the TLR pathway that are essential for effective immune defense.

Clinically, aberrant TLR signaling underpins a broad spectrum of human diseases. Genetic polymorphisms in TLR genes influence susceptibility to infectious agents. Dysregulation and hyperactivation of endosomal TLRs (notably TLR7, TLR8, and TLR9) drive pathogenesis in autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, psoriasis, and inflammatory bowel disease. In oncology, TLRs exhibit dichotomous roles, simultaneously promoting antitumor immune surveillance and facilitating tumor initiation, metastasis, and immune evasion. Moreover, age-related alterations in TLR functions form a nexus linking immunosenescence with chronic inflammatory conditions and multiple age-associated pathologies.

From a therapeutic standpoint, the potential of targeting TLR pathways is now a vibrant area of clinical investigation. Several compounds like monophosphoryl lipid A (MPLA), imiquimod, and CpG-1018 have secured approval as vaccine adjuvants or immunotherapeutic agents. Nevertheless, systemically administered TLR agonists or antagonists have faced translational challenges, with high-profile failures underscoring the necessity for precise treatment timing, patient stratification via biomarkers, and advanced delivery systems. The future trajectory of TLR-targeted therapies is shifting from broad immune activation to precision modulation, leveraging biased ligands, allosteric modulators, nanoparticle-based delivery, and incorporation of host-microbiome interactions to fine-tune immune responses for specific diseases.

Looking forward, the review anticipates that continued convergence of systems immunology, structural biology, artificial intelligence, and nanotechnology will enable unprecedented control of TLR pathways. Such advances promise to revolutionize immunotherapy for a diverse array of conditions including infectious diseases, autoimmune disorders, cancer, neurodegenerative diseases, and transplant rejection. The unfolding narrative of TLR biology exemplifies how fundamental scientific inquiry can spur transformative clinical innovations and herald a new era of precision medicine.

This seminal review, appearing in Immunity & Inflammation on April 27, 2026, therefore stands as both a definitive resource and a roadmap guiding the next frontier in innate immune research. By uniting historical insights with contemporary mechanistic understanding and translational perspectives, it affirms the centrality of TLRs at the crossroads of immunity, inflammation, and human health.

Subject of Research: Not applicable
Article Title: Toll-like receptors in innate immunity and inflammation: from fundamental biology to clinic insights
News Publication Date: 27-Apr-2026
Web References: Not provided
References: DOI 10.1007/s44466-026-00040-6
Image Credits: Professor Xuetao Cao, Chinese Academy of Medical Sciences, Beijing, China

Candida albicans is known for its ability to switch between commensalism and pathogenicity, complicating treatment strategies. Its adhesion molecules, particularly the Als (agglutinin-like sequence) family, facilitate attachment to host tissues, a critical initial step in infection development. Although the immune system deploys multiple strategies to thwart fungal dissemination, the specific cellular and molecular players that achieve this control remain incompletely characterized. This study uncovers that eosinophil surface receptor CD48 binds directly to the fungal Als6 adhesin, an interaction that is pivotal in mounting an effective antifungal response.

Through a combination of sophisticated in vitro assays and rigorous in vivo mouse models, the researchers demonstrate that CD48-expressing eosinophils recognize and interact with Candida albicans via Als6. This binding event triggers a cascade of immune responses resulting in fungal killing, including the release of cytotoxic granules and pro-inflammatory mediators. Notably, mice deficient in eosinophils or specifically lacking CD48 expression exhibit heightened susceptibility to systemic candidiasis, underscoring the protective role of this receptor-ligand axis.

One of the most compelling aspects of this research lies in the characterization of the Als6 protein not merely as an adhesin but as a direct ligand for an immune receptor. Als6’s identification as a target of eosinophil CD48 challenges conventional paradigms focused solely on fungal virulence factors and highlights a sophisticated mechanism by which the immune system exploits fungal surface molecules to detect and eradicate pathogens. This finding suggests a dual role for Als6 in facilitating adhesion and inadvertently marking the fungus for immune attack.

Eosinophils have historically been relegated to a role in allergic inflammation and defense against parasitic helminths. However, mounting evidence positions these granulocytes as versatile players in antiviral, antibacterial, and antifungal immunity. The current study solidifies this perspective by providing molecular evidence positioning eosinophils as frontline defenders against Candida albicans, especially in systemic infection contexts where rapid containment is paramount for host survival.

Mechanistically, the interaction between CD48 and Als6 promotes eosinophil adhesion and activation. The engagement stimulates intracellular signaling pathways including those that mobilize reactive oxygen species and facilitate degranulation, releasing enzymes like major basic protein that are toxic to fungi. This immune assault not only impedes fungal proliferation but also helps in recruiting additional innate and adaptive immune cells to the site of infection, orchestrating a multifaceted defense strategy.

Importantly, the researchers employed knockout mouse models to dissect the contributions of eosinophil subsets and receptor specificity. Eosinophil depletion or genetic ablation of CD48 resulted in uncontrolled fungal growth and increased mortality in systemic candidiasis models. These findings provide direct causal links between eosinophil-CD48 interactions and host resistance, highlighting the therapeutic potential of augmenting this pathway to enhance antifungal immunity.

The study’s in vitro data complemented the in vivo observations, showing that purified eosinophils incubated with Candida albicans strains deficient in Als6 adhere less efficiently and exhibit impaired fungicidal activity. Restoration of Als6 expression rescues eosinophil binding and killing, confirming the specificity of the CD48-Als6 molecular interaction. This precise receptor-ligand pairing offers an attractive target for interventions aiming to boost immune recognition of fungal pathogens.

Beyond immunological insights, this research has significant clinical implications. Systemic candidiasis remains a major cause of morbidity and mortality in hospitalized patients, with limited therapeutic options and rising antifungal resistance. By defining a novel immune recognition mechanism, the authors provide a framework for designing new immunomodulatory therapies that harness or mimic the CD48-Als6 interaction to bolster host defenses and reduce fungal burden.

The discovery of eosinophil CD48 as a key mediator of antifungal defense calls for reevaluation of current antifungal strategies that largely ignore the contribution of granulocytes other than neutrophils. Therapeutic strategies that preserve eosinophils or enhance CD48 expression and signaling may improve outcomes in patients vulnerable to systemic candidiasis. Moreover, understanding how fungal pathogens like Candida albicans might evade or suppress this immune axis could reveal new mechanisms of pathogenicity and immune escape.

This research further emphasizes the complexity of the host-pathogen interface, where fungal surface proteins serve multiple roles beyond virulence factors—they also become critical ligands for immune receptors. Investigating whether other members of the Als family or fungal adhesins interact with immune cells similarly could broaden our understanding of fungal immunosurveillance and potentially identify other exploitable targets for therapy.

The work by Zaffran and colleagues is a testament to the power of interdisciplinary collaboration involving immunologists, microbiologists, and molecular biologists. Their integration of cellular assays, genetic mouse models, and fungal molecular biology not only elucidates a new dimension of eosinophil function but also paves the way for future studies aimed at harnessing granulocyte responses in combating systemic fungal infections.

As systemic candidiasis continues to pose global health challenges, particularly among immunocompromised populations including transplant recipients, cancer patients, and individuals with HIV/AIDS, novel insights such as these are invaluable. They inform both fundamental immunology and translational medicine, enhancing our armamentarium against fungal diseases that have eluded effective control for decades.

Looking ahead, clinical trials evaluating agents capable of upregulating CD48 or enhancing eosinophil function could test the relevance of this axis in human disease. Similarly, diagnostic approaches leveraging CD48-Als6 interactions might enable early detection or monitoring of fungal infections, improving patient management. Personalized medicine approaches could also emerge, tailoring treatments based on individual immune profiles including eosinophil abundance and function.

In conclusion, the identification of eosinophil CD48 interactions with Candida albicans Als6 as a protective mechanism against systemic candidiasis represents a breakthrough in fungal immunology. This work reframes eosinophils as vital antifungal effector cells and opens new therapeutic vistas. As the burden of fungal infections grows globally, such fundamental discoveries illuminate a path towards more effective and targeted interventions that leverage the nuanced interplay of immune recognition and fungal virulence.

Subject of Research: Eosinophil-CD48 receptor interactions with Candida albicans Als6 adhesin and their role in protection against systemic candidiasis.

Article Title: Eosinophil CD48 interactions with Candida albicans Als6 is protective in vitro and in mouse systemic candidiasis.

Article References:
Zaffran, I., Gaur, P., Ofori, P. et al. Eosinophil CD48 interactions with Candida albicans Als6 is protective in vitro and in mouse systemic candidiasis. Nat Commun 16, 9291 (2025). https://doi.org/10.1038/s41467-025-64276-3

Image Credits: AI Generated